LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004 A.M. Arance Fernandez,S.J. O'Day,L. de la Cruz Merino,T. Petrella,R. Jamal,L. Ny,A. Carneiro,A. Berrocal,I. Márquez-Rodas,A. Spreafico,V. Victoria Atkinson,F. Costa Svedman, A.D. Smith,K. Chen,S.J. Diede,C. Krepler,G.V. LongAnnals of Oncology（2020）引用 22|浏览52暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
